Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11841644 | 0.83 | CYP1A2 (0.71) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL28078211 | 0.82 | CYP1A2 (0.69) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| Ammonia Solution, Strong SCHEMBL28111982 | 0.82 | CYP1A2 (0.69) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL27735725 | 0.82 | CYP1A2 (0.69) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL11042365 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL12872719 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNAALDH1A1GPR84KMT2A | |
| SCHEMBL29216003 | 0.80 | CYP1A2 (0.67) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL1050338 | 0.80 | CYP1A2 (0.67) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL917082 | 0.79 | GPR84 (0.68) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL4283121 | 0.78 | CYP1A2 (0.64) | CYP1A2LMNAALDH1A1GPR84MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118325313-A | Polylactic acid composition and application thereof in degradable food packaging | 山东铭达包装制品股份有限公司 | 2024-07-12 | — | — | CN | claimed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | claimed |
| CN-107298656-A | For pyrimidine intermediate and for pyrimidine intermediate, for pyrimidine, for the preparation method of pyrimidine hydrochloride | 四川同晟生物医药有限公司 | 2017-10-27 | — | — | CN | claimed |
| CN-106831607-A | A kind of synthetic method of 6 chloromethyluracil | 山东创新药物研发有限公司 | 2017-06-13 | — | — | CN | claimed |
| EP-3881848-B1 | METHOD FOR PRODUCING OROTIC ACID DERIVATIVE | RESONAC CORP (JP) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025136936-A1 | AGONISTS OF TREM2 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-01 | — | — | US | disclosed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4472627-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| US-4419351-A | ANTITUMOR AGENTS | RESEARCH CORPORATION (US) | 1983-12-06 | — | — | US | disclosed |
| US-4045556-A | ANTIDEPRESSANTS, PYSCHOSTIMULANTS; SILYLATION | SCHWERTNER EBERHARD | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, SLC28A1 | CYP1A2 2013/4885LMNA 3418/4885ALDH1A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.